The AB248 mouse surrogate (CD8-mIL2) demonstrated robust activity in several models (Fig. 4D, G, and J), and therapy was associated with increased numbers and functions of tumor antigen–reactive CD8+ TILs (Fig. 6C–J), including the emergence of a population characterized by a “better effector” signature (Fig. 6D and H; ref. 42). The gene discussed is CD8A; the disease is neoplasm.